The medical research community on BrightTALK brings together medical and research professionals. Find relevant webinars on medical research, laboratory science, continuing medical education and more presented by recognized medical researchers. Join the conversation by participating in live webinars and round table discussions on the latest in medical devices, medical research practices and trends in the healthcare industry.
Childhood cancer and pediatric cancer are general terms used to describe a wide range of neoplasms found in children and teenagers. Occurring in approximately 1 in 300 people under the age of 20, compared to 1 in 6 adults, pediatric cancers are more rare than adult cancers. Because less is known about pediatric cancers, diagnosis can be quite challenging for pathologists.
This presentation covers the basic science, as well as facts and statistics about pediatric cancer. We will discuss how the utility of immunohistochemical testing along with the application of novel antibodies can contribute to accurate diagnosis and survival rates of pediatric cancer patients.
Are you new to publishing your research? Struggling to select a journal or understand Peer Review? In this webinar you’ll hear practical tips from top journal editors who’ll guide you through the publishing process and help you discover all you need to know to successfully publish your next article.
You’ll learn more about:
•Where to start if you’re thinking of publishing your research
•Selecting the right journal
•Writing and submitting your article
•Tools to help you through publication and beyond
Plus you’ll have the chance to ask the editors your questions and connect with fellow researchers attending from across the globe. Sign up today to reserve your place!
Across all industries, people are changing the ways they engage with products, services, and brands. Meanwhile, the digital revolution is blurring the lines between personal and professional spaces. To stay relevant, pharmaceutical companies must re-evaluate their traditional commercial models and address the changing expectations of their customers—at scale. In this podcast, we’ll explore opportunities pharma marketers have to create engaging experiences that will deliver new types of value to meet their targets’ evolving expectations.
During this webinar we will discuss the development of the Caltech High-Speed Multi-Color Camera (CHIMERA), using two Andor iXon Ultra 888 EMCCDs, for ground-based searches for occultations of sub-kilometre-sized KBOs, which it achieves through monitoring thousands of stars simultaneously.
CHIMERA has completed 20 nights of observing in 2015 and 2016, with an additional 50 nights observing to be completed by July 2018, yielding a final data set likely to have more than 100 occultation events.
For several years, professional astronomers have been looking to Andor as a source of extreme performance, exceptionally robust off-the-shelf detector solutions, utilized across many of the key observation sites worldwide. We will provide an overview of the key high-sensitivity, high-temporal-resolution detector technology types, used in diverse applications such as adaptive optics wavefront sensing, solar exploration, high-time-resolution astrophysics, transit exoplanet discovery, gravitational lensing and even customized guide cameras.
The ImageStream® and FlowSight® are multispectral imaging flow cytometers that generates high resolution images of cells at a rate of 1000’s of cells per second. This allows for the rapid acquisition of tens of thousands of images per sample. Using the IDEAS® image analysis software, the system calculates features based not only on fluorescence intensity but the morphology of that fluorescence as well. This novel approach is able to seamlessly combine the quantitative power of flow cytometry with the high content information associated with microscopy. The system can collect data on a wide range of applications including nuclear localization during a signal transduction cascade, measuring colocalization of two probes, or quantify features on the phagocytosed particles in macrophages.
Hear from experts at Wiley, Publons and ORCID about how to get recognition for review, why it’s important and how it can benefit your research profile.
Peer Review Week is back! The theme this year is ‘Recognition for Review’ and to celebrate, we’re exploring why recognition matters and how to get it.
This webinar will explore:
The researcher’s view of why recognition for reviewing is important – why should you care, and what types of recognition are the most beneficial
How journals recognize reviewer activity – find out what journals are doing to help support their reviews and recognize their contribution
How organizations are helping to facilitate review recognition - hear from two organizations (Publons and ORCID) about their approaches to public recognition for review activity, and how this can benefit your research profile.
During radiation therapy, the patient’s anatomical state is not static. Many different factors contribute to a shifting picture, and it is essential to account for uncertainties in order to ensure the quality of the treatment plan.
In the first half of this webinar, Niek Scheuder, Chief Medical Physicist, will share his experience from implementing an adaptive planning workflow with RayStation at the Provision Center for Proton Therapy.
In the second half, Cameron Ditty, Senior Physicist, will explain the concept of robustness in RayStation, illustrating with practical examples.
Robust optimization handles possible variations that are not sufficiently accounted for by PTV. The resulting plan maintains target coverage while reducing dose to critical structures, even if anatomical changes or positional errors occur.
Demystify the process of writing and submitting your research with practical tips on selecting the right journal, handling feedback, bouncing back from rejection and streamlining the writing process.
Wiley Author Services presents Publishing Secrets for Early Career Researchers in Nursing. If you’re new to research or want to know more about the process, this webinar will give you practical guidance on:
•Selecting the RIGHT Journal
•Preparing your article – How to follow author guidelines
•Peer Review/Rejection – How to address reviewers comments
•Post publication and SEO – How to promote your work
With expert advice from top editors in the nursing research community you’ll discover all you need to help you successfully publish your next article.
Susan Gennaro, RN, PhD, FAAN
Dean and Professor, Boston College
Editor-in-Chief of Journal of Nursing Scholarship
Bernadette Mazurek Melnyk, PhD, RN, CPNP/PMHNP, FAANP, FNAP, FAAN
Dean, Associate Vice President for Health Promotion, Chief Wellness Officer, Ohio State University
Editor-in-Chief of Worldviews on Evidence-Based Nursing
Charon A. Pierson, PhD, GNP, FAANP, FAAN
Journal of the American Association of Nurse Practitioners
Professor Roger Watson,University of Hull
Faculty of Health and Social Care
BSc, PhD, RN, FRSB, FFNMRCSI, FRSA, FHEA, FEANS, FRCP Edin, FRCN, FAAN
Editor-in-Chief of Journal of Advanced Nursing
This presentation describes critical factors for selecting microcarriers, as well as starting protocols to help you optimize the attachment and expansion of cells in spinner flask and bioreactor environments.
In addition, you’ll learn about new dissolvable microcarrier technology, which provides unique advantages for cells that cannot be easily separated from standard microcarriers.
Jennifer Weber is a senior development scientist with Corning Life Sciences. She has helped develop a variety of products for culturing advanced cell types including Corning® Synthemax™, a synthetic, xeno-free surface, and Corning stemgro ® hMSC, a serum-free, chemically defined medium for hMSC culture.
She recently transitioned to microcarrier product development and customer support for bioprocess applications. As part of this role, she facilitates customer adoption of Corning products for specific applications through protocol development, on-site technical support, and in-house customer-driven projects.
Video content accounted for 64% of all the world’s internet traffic in 2014 and is expected to grow to 80% by 2019. As the way in which we connect and digest information evolves, high quality mobile video capture and advanced digital analysis offers ever more authentic, intimate and rich insights into the customers’ world. This webinar will focus on:
– How emerging technology can enable us to realise the true value of ‘video data’ in our analysis and beyond
– How mobile technology can be used to get you closer to your customers and their real world experiences right from the earliest stages in product development
– How real world video content can engage your key stakeholders and ensure customer insights drive action
In the first in a series of webinars showcasing presentations from the PMB 60th Anniversary Symposium, Steven Meikle will examine the progression of medical physics over the last 60 years. He will discuss key developments in radiation therapy, cancer diagnosis and surgery, and describe some of the underlying technologies that enabled this medical physics revolution.
Medical doctor Dheerandra Prasad talks about clinical prospects and his clinical experience of the Leksell Gamma Knife® Icon™ for precise, frameless and frame-based stereotactic radiosurgery of the brain.
Leksell Gamma Knife Icon combines the unprecedented accuracy of Gamma Knife with integrated immobilization, workflow and imaging technologies to provide even greater clinical flexibility for brain radiosurgery. This is due to a number of advancements, including on-board cone beam computer tomography, a thermoplastic mask system and an infrared-based high-definition motion-management system for patient tracking during treatment, which provide the opportunity to perform frameless and fractionated radiosurgery, as well as frame-based and single-session treatments, and to perform online adaptive planning.
Based on his experience as a radiation oncologist and a neurosurgeon, Dr Prasad discusses how these novel features of Gamma Knife Icon have opened up the possibility of extending Gamma Knife treatment to more patients and new indications. He will explain how the on-board CBCT imaging capabilities of Gamma Knife Icon have improved imaging workflows for both frame-based and frameless treatments at his clinic, and how the thermoplastic mask system has enabled him to treat targets outside the range of frame fixation. He also will describe how the ability to fractionate treatments has allowed him to expand his case mix, for example to patients with tumours that are situated close to critical structures, allowing such patients to benefit from the superior dosimetry of Gamma Knife.
Drawing from individual case studies and his personal experience, Dr Prasad will illustrate how Leksell Gamma Knife Icon is a valuable and flexible tool for brain radiosurgery and its role alongside linac-based stereotactic radiotherapy in today’s radiation oncology centres.
Diabetes is one of the most prevalent and most costly conditions worldwide – with a prevalence equating to 8.5% of the global population. Due to the complex nature of diabetes, with numerous co-morbidities and its asymptomatic nature, accurately modelling and therefore discerning which interventions are most effective, in terms of cost and patient impact is an equally complicated process.
This webinar will explore the patient pathway and how effective modelling – when pharma works together with healthcare stakeholders – can improve outcomes for both patients and the healthcare system as a whole.
This briefing reviews recent industry transformations, changes in business models, growth opportunities, and key predictions for the point-of-care testing industry. We will also be joined by Paul Pickering, president and CEO, Ubiquitome, and Herbert Torfs, VP Business Development and Strategy, GenePOC, who will discuss their experience with market trends, regulatory road blocks, and unaddressed needs in the US, Europe, and developing and underdeveloped nations.
Fully integrated with Salesforce, DocuSign helps users close more deals, faster. Your customers can sign contracts within minutes from anywhere, anytime and on any device. Sending a contract for electronic signature from Salesforce is simple: just click “Send with DocuSign” from any object. You can even generate and send contracts synced with data from Salesforce. When you automate time-consuming manual workflows, you eliminate rekeying of data and increase your productivity.
Join DocuSign and Outbrain, the global leader in content marketing, for a compelling webinar presentation and discussion.
This webinar will feature guest speaker Harel Shaked, Technical Project Manager at Outbrain. He will review how Outbrain:
- Improved sales productivity “with the click of a button” to send and sign contracts and agreements
- Began closing deals within minutes from the time an order is sent
- Lowered contract processing time by several hours
Register now to learn how Outbrain utilized DocuSign to improve the efficiency and effectiveness of their sales operations.
The need to securely share your files quickly and easily while knowing what's going on with your business is extremely important. DocuSign's integration with Box allows you to select documents from Box you want to sign or send for signature and prepare it in just a few clicks. Completed documents automatically save back to Box and can be accessed from anywhere, on any device.
Join this webinar to learn:
- How to securely share files quickly
- How to be more productive regardless of what device or application you're using.
- How Salesforce automatically creates a workflow process with Box and DocuSign
See how the DocuSign and Box integration can help you improve contract processes, keep all documents digital and help you get business done in 2016.
Predictive assays are a key element of personalized healthcare because these assays aid physicians in selecting individuals who are most likely or least likely to benefit from specific therapies. In addition to analytical validation, predictive assays require clinical validation to establish their clinical utility. Krista Acosta, Manager, CDx Pharma Services Assay Development, Nicole Schechter, PSM, PMP, CDx Director, Project Leader and Alton Yates PhD, Senior Manager, Clinical Sciences Management, will address the development and performance differences between predictive assays developed under in vitro diagnostic regulations and laboratory developed tests.
Are you prepared for the 2017 open enrollment season? Health plans and health exchanges expect member rates to increase upwards of 60 percent this year alone. Balancing this increase along with unexpected events like staff reductions, strikes, unforeseen or special projects can add additional complexity during your busiest season. We want to help you be prepared.
Register for this live webinar hosted by Dell Services and discover how to take control of the member experience, increase organizational flexibility, and reduce your costs by leveraging innovative staffing services. Our panel of industry-leading experts will review the state of the marketplace, share real-life success stories, and provide tips on ensuring your full-time and/or temporary staff is ready to handle this season’s surge in demand.
By attending this webinar, you will learn:
• Tips to prepare for open enrollment and other special projects
• When and when not to outsource
• Common pitfalls to avoid related to staffing
• Secrets to ensure claims staff productivity
• David Buchanan, Health Plan Innovation & Consulting, Dell Services
• Donna Reed, Managing Director, Health Plans, Dell Services
• Anna Mathy, Healthcare Staffing Services Sr. Leader, Dell Services
Questions this briefing will address:
· What are the key challenges the CMOs are likely to face in the near- and long-term future? How can CMOs strategize to overcome these hurdles?
· What growth opportunities exist in the pharmaceutical contract manufacturing industry?
· In what ways is the pharmaceutical contract manufacturing industry likely to change to meet industry trends and dynamics?
· Who are the game-changing companies, and what are the disruptive technologies and business models?
· How should CMOs strategically position their assets with pharma companies?
Vitamin E is a powerful antioxidant that supports your health; however, intake still remains low among consumers globally. There is an ongoing discussion about the optimal vitamin E status and its role in addressing liver and brain health beyond nutritional recommendations.
New and ongoing research suggests that vitamin E at higher doses may help individuals at risk, such as those with age-related macular degeneration, cognitive impairment, and non-alcoholic fatty liver. It is important to revisit the required intake levels for vitamin E for these conditions and further research is needed to support qualified health claims.
Join us for the first in our webinar digest series to hear Prof. Jeffrey Blumberg, DSM’s Prof. Manfred Eggersdorfer and Jacob Bauly discuss the emerging health benefits of vitamin E.
This information is solely for scientific informational purposes only and not intended for marketing and/or sales claims purposes.
Join us for a one-hour live debate on Cancer Treatment Access: Right Strategy, Right Approach, Right Outcomes.
To ensure funding and patient access to innovative cancer therapies, industry now have to navigate a new English cancer-treatment funding ecosystem, engaging with NICE and NHS England to realise a yes, no or conditional arrangement.
How can oncology treatments achieve a positive NICE appraisal in the new world and what will the mechanics of RWE be in the event of conditional funding via the reformed cancer drugs fund?
Cell culture media is required for successful and reproducible research but the catalog is full of acronyms and various formulation tables. Classical mammalian cell culture media formulations are very diverse both in terms of the number available and the concentration of constituents. Additionally, each medium was designed for specific cell types and culturing conditions.
This webinar will cover:
•The composition, characteristics, environmental factors, and additional supplements required to create optimal conditions for growth and productivity.
•Determining the right formulation for your application.
•Serum usage and helpful tips for optimizing your culture conditions.
Brian Posey is a Product Development Manager for cell culture media at Corning Life Sciences. Brian has over 10 years experience in cell biology and industrial scale cGMP manufacturing of both liquid and powder cell culture media. Since joining Corning in 2012, Brian has led numerous innovative technology projects for the media business ranging from customer technology transfer for production scale-up to developing new serum-free media for industrial and stem cell lines.
Traditional models of cognitive behaviour remain meaningful, but they can fail to deliver strong links between ‘smart’, cognitive-based factors of judgement and the decision-making associated with actual behaviour change.
In contrast, behavioural economics accounts for the ‘lazy’ judgments and thoughts that occur at an automatic level, but can over-weight the prevalence of such behaviour.
On October 4 Cello Health Insight, in association with PMGroup, will host a free webinar on applying adaptive and integrated behavioural models to qualitative enquiry.
It will look at how to achieve a better understanding of what drives therapeutic decision-making and how medical marketing, digital and PR initiatives can change future behaviours in favour of achieving target sales.
Human pluripotent stem cells (hPSCs) are traditionally co-cultured with mouse embryonic fibroblast cells (MEFs). Feeder layers introduce variability into the culture and increase the risk of contamination, which hinders the applicability of hPSCs in cell therapy and regenerative medicine. Fortunately, a new advanced surface/medium combination from Corning can help you overcome these limitations.
This webinar will introduce two xeno-free hPSC culture products- Corning® PureCoat™ rLaminin-521 cultureware and Corning® NutriStem® XF medium. Corning PureCoat rLaminin-521 cultureware are ready-to-use, pre-coated rLaminin-521 vessels available in multiple scalable formats. Corning NutriStem hPSC XF medium is a serum-free, xeno-free hPSC culture medium. We will demonstrate long term feeder-free culture and characterization of hPSCs in three different surface-medium combinations
1.Corning® Matrigel® matrix with Corning NutriStem hPSC XF medium
2.Corning rLaminin-521 (human) with Corning NutriStem hPSC XF medium
3.Corning PureCoat rLaminin-521 cultureware with Corning NutriStem hPSC XF medium
Dr. Himabindu Nandivada is a Senior Development Scientist at Corning Life Sciences. She received her Ph.D. and M.S. from University of Michigan in Ann Arbor in Chemical Engineering. Her research interests are in developing biomimetic interfaces for cell culture applications and human pluripotent stem cell culture. Dr. Nandivada has authored 13 peer-reviewed publications with over 2,000 citations, 3 book chapters and 3 patents.
Interaction between antigen-specific T cells and antigen presenting cells (APC) cognate ligand involve reorganization of the cytoskeleton and recruitment of adhesive and signaling molecules to the site of intercellular contact. Sustained adhesion of T cells to APCs and formation of the immunological synapse after T cell receptor stimulation are required for the antigen-specific response. One way to measure an immunological synapse is by fluorescently labeling the molecules that have been recruited to the synapse and imaging by fluorescence microscopy. However, immunological synapses are rare and therefore difficult to analyze objectively and statistically by traditional microscopy methods. To overcome these problems, we employed the Amnis brand imaging flow cytometers to objectively collect imagery of large numbers of cells. We report the percentage of T cells involved in an organized immunological synapse, the recruitment of adhesion molecule LFA-1 and signaling molecule Lck to the synaptic complex and subsequent translocation of NFkB from the cytoplasm to the nucleus in the T cell. In this study, Raji B cells loaded with Staphylococcal enterotoxin B (SEB) were incubated with human T cells to create T cell-APC conjugates. Cells were stained in various combinations for CD3, CD19, Actin, LFA-1, Lck and NFkB. Results from the FlowSight and the ImageStream imaging flow cytometers are compared. Using the FlowSight imaging flow cytometer we demonstrate image-based parameters that were used to assess the frequency of conjugates with an organized immunological synapse in an objective and statistically significant manner. Employing the ImageStream imaging flow cytometer we further evaluate the specific location of the adhesion and signaling molecules LFA-1 and Lck within the immunological synapse complex in T cells and measure the nuclear localization of NFkB in the T cell.
Prostate cancer is the most common cancer among men. Fortunately, it can be detected early by monitoring PSA levels. However, PSA tests have limited specificity for cancer, resulting in numerous unnecessary biopsies each year, which creates the need for a more precise test to help with prostate cancer detection. In this webinar, Dr. Vernon Mustoe will discuss how a simple blood test can help provide more accurate information on what an elevated PSA level might mean and the probability of finding prostate cancer on biopsy. P.A.C.E. credit is available for your participation.*
Dr. Vernon Mustoe is one of Beckman Coulter’s medical affairs managers, supporting customers with advanced clinical and technical issues. Having obtained his undergraduate and graduate degrees from New York University, he spent over 23 years in the clinical laboratory. Most recently, he was the Director of Clinical Chemistry and Assistant Director of Laboratory Services at Sisters of Charity Medical Center in Staten Island, N.Y. He has also taught Clinical Pathology at the Bayley Seton Physician Assistant School, as well as Clinical and Anatomic Pathology at the College of Staten Island Campus of the City University of New York. Dr. Mustoe has been with Beckman Coulter since 2001.
This briefing will answer the following key questions:
· How are technology trends, such as new sequencers on the high end (Illumina HiSeq X Ten) and low end (Illumina MiniSeq, Oxford Nanopore MinION), impacting NGS services providers?
· How will the market change in accordance with the declining cost of sequencing, which hit the $1,000 genome mark?
· When will the $100 genome be realized, and how will that achievement occur?
· What are “answer-based services,” and why should NGS service providers be concerned about an impending paradigm shift in the way research questions are answered?
· How should NGS service providers be positioning now in order to take advantage of the various changes expected in the marketplace over the next 10 years, as well as the growth opportunities available from these changes?
In this webinar, Dr. Barbara Zimmer will discuss the mechanisms of antibiotic resistance that are most concerning to the Centers for Disease Control (CDC). Attendees will receive an in-depth review of the classes of beta-lactamase resistance found in Enterobacteriaceae and the challenges associated with detection in the laboratory. P.A.C.E. credit is available for your participation.*
Discover how to promote your research, receive practical tips for working with the media and learn more about boosting your own research profile.
In this webinar you’ll receive the practical advice you need to ensure you work effectively with your institution or publisher to promote your research. Hear why you should get involved in Standing up for Science throughout your career and understand how to responsibly communicate with the media.
Hear from experts at Wiley and Sense About Science on:
•How to make your research have an impact
•Assessing how newsworthy your research is – finding the ‘hook’
•Understand how the media works and receive practical advice on working with journalists
•Your role as a scientist in society and the importance of sharing your research
•Responsible communication of your research
Extreme Light Infrastructure – Nuclear Physics (ELI-NP) is the most powerful laser system dedicated to laser-matter interaction and nuclear physics studies. With a recent investment in creating a new cutting-edge research facility ELI-NP is now seeking the very best minds to join their crew in Romania.
Join Nicolae Victor Zamfir, Project Manager at ELI-NP, to discuss the incredible work being done in understanding the fundamental processes involved in light-matter interaction. You'll find out about the new opportunities available as well as:
- what ELI-NP is looking for in your application
- the benefits of working for ELI-NP
- how to apply
Continuing our series of webinars showcasing presentations from the PMB 60th Anniversary Symposium, Brian Pogue discusses the evolution of diagnostic imaging over the last 60 years. He will present examples of successful medical imaging technologies, explain how the use of contrast agents can improve delineation and function assessment, and present some fundamentally new physical imaging systems.
Observable foreign and particulate matter has for a long time been recognized as a critical quality attribute for production of injectable protein formulations. Recently, a focus shift towards these particles and even smaller particles (particulate matter or subvisible particles) has been seen from the pharmaceutical industry, academia and the different regulatory bodies. Two of the central documents in this context are:
1. The FDA Guidance for Industry on Immunogenicity Assessment for Therapeutic Protein Products1 and
Single-Use Process Analytical Technologies (PAT) tools have a great potential to not only increase process understanding at the seed stage but also simplify cell culture operations. By utilizing PAT, the risk from bioburden or contamination can be significantly reduced and the overall operating efficiency increased. In fact, PAT also provides a data-driven platform to integrate Process Development and Manufacturing Operations that can mitigate risks associated with technology/process transfer.
Continuous bioprocessing offers potential to enhance productivity and product quality uniformity while simultaneously decreasing facility footprint and associated operational overhead. Advances in technology and increasing commercial pressures are leading to an increased interest in continuous processing across the biopharmaceutical sector. A number of companies are exploring and advancing continuous bioprocessing and this presents a range of opportunity and challenges, including the use of Process Analytical Technology (PAT) for process characterization, process control, and process robustness, in support of a Rapid Product Release (RPR) strategy.
Sourcing for the manufacture and control of Antibody-Drug Conjugates (ADCs) used in clinical trials requires strategic planning, establishment of a specialized support network, and execution of several interdependent tasks. ADCs are complex molecules, a fusion of a biological, the monoclonal antibody (mAb), and of small molecules, the linker and the toxic payload. Facilities of acceptable standards for the handling of high potency materials need to be engaged, and there is a limited supply currently. This is further complicated by the fact that there is not one contract facility that has fully integrated services, a “one-stop shop” capable of mAb production, linker and/or payload synthesis, conjugation of mAb to linker-payload to make the Drug Substance, and finally, formulation of the ADC to make the Drug Product. Strategizing the best outsourcing practices for producing and testing ADCs, and establishing guiding principles for externalization to ensure the selection of the right CMOs for ADC outsourcing and technology transfer, will be further discussed.